It has been long recognized that disruption of splicing mechanisms can cause disease, including cancer. The Computational RNA Biology research group led by Eduardo Eyras at the GRIB (UPF:IMIM) has recently performed an exhaustive analysis of the functional impacts produced by alternative splicing changes in tumors (Climente-Gonzalez et al. 2017). They found that cancer specific alternative splicing changes lead frequently to shorter protein products and sometimes to a non-coding transcript.
You can read more about this latest paper in their latest group’s blog entry.